Highlights Newsletter 3

This newsletter presents you the following key sessions:

1. Podcast with Dr. Daniele Rossini about modified FOLFOXIRI plus panitumumab (mFOLFOXIRI/PAN) versus
    mFOLFOX6/PAN as initial treatment of unresectable RAS/BRAF wild-type metastatic colorectal cancer
    (mCRC) patients (TRIPLETE study)

2. Pooled quality of life data reinforce the clinical outcomes obtained with trifluridine/tipiracil in patients
    with metastatic colorectal cancer

3. Pemigatinib provides durable responses and prolonged OS in previously treated patients with advanced
    or metastatic CCA and FGFR2 fusions or rearrangements

4. Tislelizumab plus chemotherapy demonstrates superior efficacy compared to placebo plus chemotherapy
    as first-line treatment for advanced or metastatic oesophageal cancer